AOBiome

AOB Pharma reveals new insights via metabolomic analysis of B244, supporting clinical readouts & suggesting investigation of potential new avenues for treatment

https://health.einnews.com/pr_news/814753976/aob-pharma-reveals-new-metabolomic-insights-of-b244-suggesting-investigation-of-potential-new-avenues-for-treatment

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

The newly issued patent covers Composition of Matter for AOBiome’s proprietary strain of Ammonia Oxidizing Bacteria (AOB), along with additional claims pertaining to a variety of related methods including use thereof in changing a composition of a skin microbiome of a subject, inhibiting microbial growth on a subject’s skin, and treating or preventing a skin disorder.

AOBiome’s clinical candidate B244 has demonstrated clinical efficacy on multiple therapeutic indications including: Mild-to-Moderate Atopic Dermatitis and associated Moderate-to-Severe Pruritus, and mild-to-moderate Acne Vulgaris.

AOBiome is currently preparing for its Phase 3 trials for the treatment of Atopic Dermatitis (Eczema) and associated Pruritus (Itch).

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244 AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244 Apr 06, 2023 (PRNewswire via COMTEX) -- PR Newswire CAMBRIDGE,...